Jerini

Peptidomimetics and small molecules as drug candidates

jerini Logo
About Jerini

The peptide experts

With its technology platform Peptides-to-Drugs (P2D) the biotechnology company pursued disease indications for which limited, inadequate, or no treatment options exist, most notably within the ophthalmology, oncology and inflammatory therapeutic areas.

Management

Jens Schneider-Mergener

bmp Ventures Team

Oliver Borrmann

Founded

1994

Invested

2000

Stage

Expansion

Industry

Life Sciences

Status

Exited (2005 – IPO)